Der er i dobbeltblinde og åbne kliniske forsøg rapporteret maligniteter hos 66 ud af 2. 688 abataceptbehandlede patienter gennem 4. 764 patientår.
In double-blind and open-label clinical trials, malignancies were reported in 66 of 2,688 abatacept-treated patients during 4,764 patient-years.